Skip to main content
. 2014 Sep 16;5(20):9952–9965. doi: 10.18632/oncotarget.2481

Figure 5. Overall survival of patients stratified for the presence/absence of mutations in TP53.

Figure 5

(A), the PI3K pathway (B), cell cycle pathways (C) and MAPK associated pathways (D).